香港50指数跌至25452.00点，为2025年9月以来的最低水平。过去4周，香港股市指数（HK50）上涨0.78%，过去12个月上涨24.64%。

HK50 decreased to 25452.00 Index Points, the lowest since September 2025. Over the past 4 weeks, Hong Kong Stock Market Index (HK50) gained 0.78%, and in the last 12 months, it increased 24.64%.

恒生指数周五下跌462点，跌幅1.7%，收于26290点，连续第五个交易日下跌，触及两周低点。科技股领跌，跌幅超过3%，此前中国收紧了稀土出口管制，并加大了芯片进口限制的执行力度，以遏制对英伟达人工智能处理器等美国产品的依赖。消费类股也下跌了约2.7%，因为投资者在下周中国9月的关键数据（包括贸易、CPI/PPI和信贷数据）公布前变得焦虑。主要落后者包括中金矿业（-7.4%）、中芯国际（-7.2%）、中国虹桥（-5.9%）、快手科技（-5.4%）和腾讯（-3.6%）。尽管如此，华尔街最近创下的历史新高和10月底美联储降息的持续押注缓冲了损失。与此同时，对大陆股市的情绪保持乐观，中国基准股指在黄金周休市后徘徊在十年高点之上。本周，恒生指数下跌3.1%，扭转了前一时期的涨幅。

The Hang Seng tumbled 462 points, or 1.7%, to close at 26,290 on Friday, extending losses for the fifth straight session and hitting a two-week low. Tech shares led the slump, down over 3%, after China tightened rare earth export controls and stepped up enforcement of chip import restrictions to curb reliance on U.S. products such as Nvidia’s AI processors. Consumer stocks also lost about 2.7%, as investors turned anxious ahead of key Chinese data for September next week, including trade, CPI/PPI, and credit figures. Major laggards included Zhojin Mining (-7.4%), SMIC (-7.2%), China Hongqiao (-5.9%), Kuaishou Tech (-5.4%), and Tencent (-3.6%). Still, losses were cushioned by Wall Street’s recent record highs and continued bets for a Fed rate cut in late October. Meantime, sentiment toward mainland stocks stayed upbeat, with Chinese benchmarks hovering over decade highs after the Golden Week break. For the week, the Hang Seng fell 3.1%, reversing gains from the previous period.

香港股市周五早盘下跌249点，跌幅0.9%，至26501点，这是连续第五次下跌，也是近两周来的最低跌幅。由于交易员评估了美联储官员关于利率和美国财报季开始的言论，华尔街隔夜从历史高点下滑，市场情绪受到压力。在下周公布包括9月贸易数据、CPI和PPI读数以及信贷统计数据在内的中国关键数据之前，人们也更加谨慎。在中国扩大对技术和军事用途的稀土出口管制后，大多数行业下跌，科技股领跌。汇丰控股计划以136亿美元收购其持有多数股权的恒生银行的少数股东后，金融股下跌。跌幅最大的包括中芯国际（-4.2%）、百度（-3.4%）、阿里巴巴（-3.0%）和神州国际（-2.5%）。大陆股市的看涨情绪限制了跌幅，大陆股市在中断一周后于周四恢复交易。香港在上周强劲上涨后，本周将大幅下跌。

Hong Kong stocks dropped 249 points, or 0.9%, to 26,501 in early trade on Friday, marking a fifth straight fall and the lowest in near two weeks. Sentiment was pressured after Wall Street slipped from record highs overnight, as traders assessed remarks from Fed officials on interest rates and the start of the U.S. earnings season. Caution also grew ahead of key Chinese data next week, including September trade figures, CPI and PPI readings, and credit statistics. Most sectors dipped, led by tech after China widened rare earth export controls for tech and military uses. Financials dipped after HSBC Holdings plans a USD 13.6 billion buyout of minority shareholders in its majority-owned Hang Seng Bank. Top losers included SMIC (-4.2%), Baidu (-3.4%), Alibaba (-3.0%), and Shenzhou Intl. (-2.5%). Losses were limited by bullish mood in mainland stocks, which resumed trading Thursday after a week-long break. Hong Kong is set to end the week sharply lower, following last week’s strong gains.

周四，恒生指数下跌77点，跌幅0.3%，收于26752点，因大多数板块走弱而连续第四个交易日下跌。金融指数下跌0.7%，此前有报道称汇丰控股计划以约136亿美元收购其控股的恒生银行的少数股东。汇丰银行（HSBC）在香港上市的股票暴跌5.5%，恒生银行（Hang Seng Bank）上涨26%，花旗（Citi）分析师安德鲁·库姆斯（Andrew Coombs）指出，投资者质疑“为什么现在和这个价格”。在中国以科技和军事用途为由扩大稀土出口管制后，市场情绪恶化，科技股下跌。消费者也下跌，受制药股在获利回吐中下跌的拖累。值得注意的是，四川科伦生物科技股价下跌12.0%，紧随其后的是信达生物（-9.2%）、中药业（-7.9%）和无锡生物（-2.8%）。受黄金周支出强劲和北京方面新政策支持预期的推动，内地市场反弹至十多年来的最高点，从而限制了跌幅。

The Hang Seng lost 77 points or 0.3% to end at 26,752 on Thursday, declining for the fourth session as most sectors weakened. The financial index dropped 0.7% after reports that HSBC Holdings plans to buy out minority shareholders in its majority-owned Hang Seng Bank for about USD 13.6 billion. HSBC’s Hong Kong-listed shares plunged 5.5%, while Hang Seng Bank surged 26%, with Citi analyst Andrew Coombs noting that investors were questioning “why now and at this price.” Tech shares retreated as sentiment soured after China broadened its rare earth export controls, citing tech and military uses. Consumers were also lower, dragged by losses in pharma stocks amid profit-taking. Notably, Sichuan Kelun-Biotech tumbled 12.0%, followed by Innovent Biologics (-9.2%), Sino Biopharm (-7.9%), and Wuxi Biologics (-2.8%). Losses were capped by a rally in mainland markets to their highest in over a decade, boosted by strong Golden Week spending and expectations of fresh policy support from Beijing.